FDA Grants Breakthrough Device Designation for Merit Medical’s Wrapsody Endovascular Stent Graft

 

November 21, 2019—Merit Medical Systems, Inc. announced that it has been granted Breakthrough Device designation by the FDA for the company's Wrapsody endovascular stent graft system. The Wrapsody system is a flexible, self-expanding endoprosthesis.

As noted in the company’s announcement, Merit intends to seek an indication for use in hemodialysis patients for the treatment of stenosis within the central veins of the outflow circuit of an arteriovenous fistula (AVF) up to the superior vena cava. The Wrapsody system is nearing completion of its first-in-human studies and is not currently available for sale.

The FDA Breakthrough Device program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA provides priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions, advised Merit Medical Systems.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.